Samjin Pharmaceutical Co Ltd
KRX:005500
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Samjin Pharmaceutical Co Ltd
Operating Income
Samjin Pharmaceutical Co Ltd
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
S
|
Samjin Pharmaceutical Co Ltd
KRX:005500
|
Operating Income
â‚©20B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-4%
|
Yuhan Corp
KRX:000100
|
Operating Income
â‚©34.7B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-6%
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Operating Income
-â‚©37.5B
|
CAGR 3-Years
46%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Operating Income
â‚©237.4B
|
CAGR 3-Years
67%
|
CAGR 5-Years
25%
|
CAGR 10-Years
14%
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Operating Income
â‚©8.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-7%
|
C
|
Celltrion Pharm Inc
KOSDAQ:068760
|
Operating Income
â‚©27.5B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
47%
|
CAGR 10-Years
16%
|
See Also
What is Samjin Pharmaceutical Co Ltd's Operating Income?
Operating Income
20B
KRW
Based on the financial report for Mar 31, 2024, Samjin Pharmaceutical Co Ltd's Operating Income amounts to 20B KRW.
What is Samjin Pharmaceutical Co Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
-4%
Over the last year, the Operating Income growth was -19%. The average annual Operating Income growth rates for Samjin Pharmaceutical Co Ltd have been -12% over the past three years , -20% over the past five years , and -4% over the past ten years .